Azacitidine
VIDAZA
About: Azacitidine (Vidaza)
Azacitidine (Vidaza) is a chemotherapy drug, from a drug class called demethylation agents or hypomethylating agents. Hypomethylating agents are a low-intensive chemo-treatment designed to slow progression of cancer with as few side effects as possible. It can switch off the DNA methyltransferase protein, blocking DNA methylation and preventing cancer cells from growing and dividing. This reduces the cell growth and quantity of abnormal blood cells. Hypomethylation of DNA by Azacitidine (Vidaza) also activates tumor suppressor genes triggering an anti-tumor effect previously silenced by hypermethylation.
INDICATIONS
Myelodysplastic Syndromes (MDS) and Sub-types
Refractory Anemia with Excess Blasts (RAEB)
Refractory Anemia with Ringed Sideroblasts (RARS)
Refractory cytopenia with multilineage dysplasia (RCMD)
MDS with isolated deletion 5q (5q-syndrome)
Refractory Anemia (RA)
Refractory neutropenia (RN)
Refractory thrombocytopenia (RT)
Azacitidine is used to treat Myelodysplastic Syndrome (MDS) and MDS sub-types. Azacitidine reduces methylation in the body, which silences certain genes and turns on genes that prevent cancer cells from growing and dividing. Azacitidine reduces the amount of abnormal blood cells and is the only drug proven to extend the overall survival in high risk MDS patients.
Acute Myeloid Leukemia
Azacitidine is to treat patients with Acute Myeloid Leukemia (AML). Azacitidine works by helping bone marrow to grow normal blood cells so patients require less blood transfusions. Azacitidine also stops abnormal blood cells that grow too quickly, to improve the life quality and survival rates in patients with AML.
COMMONLY PURCHASED TOGETHER
Cyclophosphamide
Cytarabine
Decitabine
Deferoxamine Mesylate
Dexamethasone
Etoposide
Fludarabine
Fosaprepitant
Hydroxyurea
Methotrexate
Ondansetron
Palonosetron
Prednisone
REQUEST MORE INFO
Delivering the medication
YOU NEED
WHEN YOU NEED IT
even during periods of
shortages in the market.
